en Clinical Medicine Clinical Medicine مقاله پژوهشی Original Research Article <p style="text-align: justify;"><span style="font-size:16px;"><span style="font-family:Times New Roman;"><strong new="" roman="" style="font-family: " times=""><span style="color:#ffffff;"><span style="background-color:#16a085;">Background and Objective:</span></span>&nbsp;</strong><span style="line-height:150%"><span style="line-height:150%">Chronic inflammation, dyspnea and activity limitation are common phenomena in patients with chronic obstructive lung disease.&nbsp; Clinical studies suggest that Ubiquinone has anti-inflammatory and energetic properties. Here the beneficial effect of CoQ10 in patients with COPD will be studied.</span></span><br> <strong new="" roman="" style="font-family: " times=""><span style="color:#ffffff;"><span style="background-color:#16a085;">Materials and Methods:</span></span>&nbsp;</strong><span style="line-height:150%"><span style="line-height:150%">Baesd on the census method, 90 patients with moderate to severe COPD were divided into two identical placebo and CoQ10 groups. High sensitive-C-reactive protein (hs-CRP), Forced Expiratory Volume in 1 second, numerical rating breathlessness scale and &quot;the time to get exhausted&quot; were evaluated and recorded at baseline and the end of the study. The CoQ10 group received 120 mg of CoQ10 supplement per day versus the placebo group who also received a placebo (identical in look, size and taste to pharmaceutical sample) and were followed for 6 weeks. Data were analyzed using t-test, and nonparametric statistical tests. Qualitative variables were assessed by chi-square or Fisher exact tests.&nbsp;</span></span><br> <strong new="" roman="" style="font-family: " times=""><span style="color:#ffffff;"><span style="background-color:#16a085;">Results:</span></span></strong>&nbsp;<span style="line-height:150%"><span style="line-height:150%">The study included 49(53.6%) women and 41(46.4%) men, collectively 90 patients with moderate to severe COPD. The mean age was 66.97&plusmn;12.59 years in the placebo and 64.21&plusmn;11.78 years in the CoQ10 group (p=0.30). Breathlessness scale was improved in CoQ10 group (p<0.001). hs-CRP significantly declined after intervention in the CoQ10 compared to &nbsp;the placebo group (p<0.001).No serious side effects were observed as a result of CoQ10 consumption.</span></span><br> <strong new="" roman="" style="font-family: " times=""><span style="color:#ffffff;"><span style="background-color:#16a085;">Conclusion:</span></span>&nbsp;</strong><span style="line-height:150%"><span style="line-height:150%">Daily administration of CoQ10 in COPD patients increases hs-CRP and improves dyspnea and &quot;the time to get exhausted&rdquo; without side effect.</span></span></span></span></p> COVID-19, Pneumonia, Diagnosis, CT- Scan, RT- PCR 238 243 http://journal.zums.ac.ir/browse.php?a_code=A-10-6278-1&slc_lang=en&sid=1 Seyyed Gholamreza Mortazavi Moghadam gmortazavi@bums.ac.ir 5200319475328460076714 5200319475328460076714 No Birjand CardioVascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran Asghar Zarban azarban@yahoo.com 5200319475328460076715 5200319475328460076715 No Birjand CardioVascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran Reza Yaghobbi Marakieh rezayaghobbi86@gmail.com 5200319475328460076716 5200319475328460076716 No Dept. of Internal Medicine, Birjand University of Medical Sciences, Birjand, Iran Elahe Allahyari elaheh.allahyari@gmail.com 5200319475328460076717 5200319475328460076717 Yes Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran